Skip to main content
Premium Trial:

Request an Annual Quote

Affy Licenses Genisphere's MiRNA Reagents

NEW YORK (GenomeWeb News) – Affymetrix plans to offer Genisphere's miRNA reagents for use with its GeneChip miRNA 2.0 Arrays under a new license agreement, Affy said today.

The company said it expects to launch integrated reagent kits that include Genisphere's FlashTag Biotin HSR Reagents under the Affymetrix brand in early 2012.

Genisphere's reagents are compatible across a range of sample types, including formalin-fixed, paraffin-embedded fresh frozen samples and blood, for use in studies of the role of miRNAs in biological processes such as mRNA degradation, transcriptional gene silencing, translational repression, and biomarker discovery projects for translational and cancer research.

"This reagent addition provides researchers with the tools to move from a whole-genome view of complex biological systems using the GeneChip miRNA Arrays to single-gene validation with QuantiGene View miRNA Assays," Kevin Cannon, general manager of Affy's Gene Expression business unit, said in a statement.

Affy and Genisphere announced on Wednesday an agreement to exclusively license Genisphere's RNA amplification and labeling technology for use in FFPE samples.

Financial terms of the license agreement were not released.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.